［1］Petrelli F，Coinu A，Lonati V，et al.Neoadjuvant dose-dense chemotherapy for locally advanced breast cancer：A meta-analysis of published studies［J］.Anticancer Drugs，2016，27：702-708.
[2]Jiang BQ，Li ZD，Zhuang ZG.Clinical safety of docetaxel in the treatment of breast cancer［J］.Journal of Adverse Drug Reactions，2009，11（3）：165-169.［蒋蓓琦，李正东，庄志刚.多西他赛治疗乳腺癌2 种方案的临床安全性研究［J］.药物不良反应杂志，2009，11（3）：165-169.］
[3]Yanai H，Endo K，Matsumoto M，et al.The clinical utility of pegfilgrastim in combination with adjuvant FEC(100)and TC chemotherapy for breast cancer［J］.Gan To Kagaku Ryoho，2016，43：1087-1090.
[4]Alsharedi M，Gress T，Dotson J ，et al.Comparison of toxicity profile and tolerability between two standard of care paclitaxel-based adjuvant chemotherapy regimens in breast cancer［J］.Med Oncol，2016，33：27.
[5]Lambertini M，Ceppi M，Cognetti F，et al.Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients：A pooled analysis of the MIG1 and GIM2 phase III studies［J］.Eur J Cancer，2017，71：34-42.
[6]Lyman GH，Reiner M，Morrow PK，et al.The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy［J］.Ann Oncol，2015，26：1452-1458.
[7]Chinese Society of Clinical Oncology，UCLI，Chinese Anti-Cancer Association,Committee of Breast Cancer Society,et al.Consensus of Chinese experts on the clinical application of PEG-rhG-CSF with polyethylene glycol recombinant human granulocyte stimulating factor［J］.Chin J Clin Oncol，2016，43(7)：271-274.［中国临床肿瘤学会，中国抗淋巴瘤联盟，中国抗癌协会乳腺癌专业委员会，等.聚乙二醇化重组人粒细胞刺激因子（PEG-rhG-CSF）临床应用中国专家共识［J］.中国肿瘤临床，2016，43(7)：271-274.］
[8]Fernandes R，Mazzarello S，Stober C，et al.Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer：A systematic review［J］.Breast Cancer Res Treat,2017，161：1-10.
[9]Takhar H，Mislang AR，Singhal N，et al.Feasibility and kinetics of CD34+ hematopoietic progenitor cell mobilization in response to a single administration of docetaxel chemotherapy and pegfilgrastim in a contemporary cohort of patients with metastatic breast cancer［J］.Asia Pac J Clin Oncol，2017，13：79-86.
[10]Ling MS，Xu XY，Shi FX，et al.Study on the increase of renaturation efficiency of recombinant human granulocyte monoline colony stimulating factor by polyethylene glycol［J］.Pharmaceutical Biotechnology，1997，4（1）：5-8.［凌明圣，许翔裕，施凤霞，等.聚乙二醇增加重组人粒-单系集落刺激因子复性效率的研究［J］.药物生物技术，1997，4（1）：5-8.］
[11]Waller CF，Semiglazov VF，Tjulandin S，et al.A phase III randomized equivalence study of biosimilar filgrastim versus amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancer［J］.Onkologie，2010，33：504-511.
[12]Lambertini M，Bruzzi P，Poggio F，et al.Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients：A single-center experience within the GIM2 randomized phase III trial［J］.Support Care Cancer ，2016，24：1285-1294.